The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. who require oxygen therapy due to COVID-19, OR. Yancopoulos , M.D.,

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

NOVEMBER 6, 2020

“Time to referral affects how soon we can initiate multidisciplinary care, which may include medications, physical therapy and occupational therapy that are crucial for improving mobility and joint function over these children’s lifetimes.” At its core is Hospital for Special Surgery, nationally ranked No.

Nurses 52

Nurses Hospitals Disease Therapies 52

Perficient: Drug Development

JUNE 26, 2023

Our recent discussions with Chief Medical Officers, Chief Information Officers, Chief Medical Information Officers, and a VP over Nursing point to this: AI can provide a huge amount of value when it comes to care delivery (e.g., point of care). You may notice that I mentioned AI there and not, more specifically, generative AI.

Nurses 52

Nurses Doctors Hospitals Engineering 52

Olympian Clinical Research

JUNE 25, 2020

Environmental changes such as travel, hospitalization, new visitors, etc. Changes in living situation, such as moving to a new residence home or nursing home. Make time for soothing activities such as massage therapy, calming music, and reading. The introduction of a new caregiver. Misperceived threats. Fear and fatigue.

Nurses 78

Nurses Clinical Research Clinical Trials Hospitals 78

Drug Target Review

AUGUST 16, 2024

Advances in gene editing, personalised medicine, and regenerative therapies are improving patient outcomes and changing the landscape of healthcare. I graduated with my BS in physiology and later attended the University of Michigan Medical School.

Medical Schools 111

Medical Schools Nurses Research Production 111

The Pharma Data

DECEMBER 10, 2020

The next thing Sandi remembers, it was a week later and she was in the hospital. To cheer her up, the nurses decorated her room with class of 2015 memorabilia. To cheer her up, the nurses decorated her room with class of 2015 memorabilia. She spent weeks undergoing physical, occupational and speech therapy.

Nurses 52

Nurses Doctors Hospitals Therapies 52

The Pharma Data

OCTOBER 21, 2020

“I’m not surprised that they could see similar effects of therapy with patients using telemedicine as they would via in person,” said Dr. Andrew Southerland, an associate professor of neurology and public health sciences at University of Virginia Health, in Charlottesville, Va.

Therapies 52

Therapies Nurses Compliance Doctors 52

The Pharma Data

NOVEMBER 10, 2020

SAMI is a renal replacement therapy (RRT) machine manufactured and commercialized by Spectral’s wholly-owned subsidiary, Dialco Medical Inc. ( “Dialco” ). The paper describes the first month of using SAMI as part of UMMC’s PIRRT (Prolonged Intermittent Renal Replacement Therapy) program throughout April 2020.

Therapies 52

Therapies Nurses FDA FDA Approval 52

The Pharma Data

JANUARY 19, 2021

The new findings were published online recently in the Journal of Pediatric Nursing. Melissa Nishawala, director of the Autism Spectrum Disorder Research and Clinical Program at Hassenfeld Children’s Hospital at NYU Langone Health in New York City. Most families kept the cat after the study ended. © 2021 HealthDay.

Nurses 52

Nurses Hospitals Research Science 52

The Pharma Data

AUGUST 6, 2020

In 2016, data became increasingly available on the safety profile of fluoroquinolone antibiotics, specifically around inappropriate use as a first-line therapy which raised concern of potential harm to patients. Medscape and the FDA collaborative research. This target audience wrote 7.3

FDA 52

FDA Nurses Hospitals Therapies 52

The Pharma Data

OCTOBER 25, 2020

Agitation associated with delirium is commonly seen in numerous hospital settings, resulting in serious medical complications and extended hospital stays. Treatment choices are limited, and commonly used off-label therapies are not always effective or may result in prolonged, deep sedation. NEW HAVEN, Conn.,

Treatment 40

Treatment Trials FDA Hospitals 40

The Pharma Data

NOVEMBER 17, 2020

Dr. Anderson moved to North Carolina to work at Presbyterian Hospital under the direction of Dr. Klaus Wiemer in 1992. She speaks nationally and internationally on how cancer and autoimmune disease therapies affect reproductive health and fertility, ovarian aging, primary ovarian insufficiency and genetics. Karen R.

Laboratories 52

Laboratories Nurses Doctors International 52

The Pharma Data

NOVEMBER 20, 2020

Dr. Christopher Celano, associate director of the Cardiac Psychiatry Research Program at Massachusetts General Hospital, said zeroing in on the root causes of the relationship between depression and heart disease offers fresh details on a complicated interaction. Medications, talk therapy and exercise can help, Moser and Celano said.

Disease 52

Disease Nurses Research Hospitals 52

Altus Drug Development

MAY 31, 2022

This lightens the burden that patients in critical condition put on healthcare systems, giving doctors and nurses some much-needed breathing space. For healthcare professionals Value-added medicines group several choices together, creating an unprecedented amount of flexibility in therapy.

Treatment 52

Treatment Pharmaceuticals Production Doctors 52

The Pharma Data

JULY 23, 2021

. “Serious infections in children can be difficult to treat and the impact of ABSSSI among children is significant, as these infections often require IV antibiotics, resulting in hospitalization,” said Margaret Burroughs, medical director, infectious diseases, AbbVie. Use in Specific Populations.

FDA Approval 52

FDA Approval FDA Clinical Trials Trials 52

On Medicine

FEBRUARY 26, 2023

In addition to meaningful specialized treatment, Daniella uses her creative pursuits as a form of therapy, inspiring others living with chronic health issues through the use of her podcast. Rapidly, within months, her condition became more critical involving arthritis, erythema nodosum, bilateral uveitis, and intestinal issues.

Disease 40

Disease Treatment Nurses Doctors 40

The Pharma Data

NOVEMBER 30, 2020

The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid and commercial insurance payors. AdaptHealth services approximately 1.8

Compliance 40

Compliance Nurses Production Therapies 40

The Pharma Data

JULY 2, 2025

This trial was the first in its therapeutic area to use a composite primary endpoint consisting solely of major morbidity and mortality events , such as all-cause death, lung transplantation, or PAH-related hospitalization of at least 24 hours. Despite existing therapies, many PAH patients remain at substantial risk.

Trials 52

Trials FDA Licensing Licensing 52

The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that the U.S. Yancopoulos , M.D., In the U.S.

Government 52

Government Hospitals Virus Clinical Trials 52

The Pharma Data

NOVEMBER 20, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. It is one of the nation’s busiest adult solid organ transplant centers and is the primary teaching hospital for the USF Health Morsani College of Medicine. TAMPA, Fla.,

Hospitals 40

Hospitals Treatment Virus Nurses 40

The Pharma Data

AUGUST 27, 2020

The anti-PD-1 therapy combo was approved in Europe in September 2019 based on findings from the pivotal Phase III KEYNOTE-426 trial, which demonstrated that the drug reduced the risk of death by 47% compared with sunitinib in the indication. Kidney cancer UK has slammed the decision. Source link.

Clinical Trials 52

Clinical Trials Nurses Trials Treatment 52

The Pharma Data

AUGUST 11, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.

Therapies 52

Therapies Trials Disease Treatment 52

The Pharma Data

NOVEMBER 21, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. Regeneron Pharmaceuticals, Inc. Food and Drug Administration (FDA).

FDA 40

FDA Clinical Trials Hospitals Production 40

The Pharma Data

NOVEMBER 19, 2020

A study out of Rutgers University found that healthcare staffers, especially nurses, have a higher prevalence of COVID-19 than non-healthcare workers. The study data came from a prospective study of participants at Rutgers and affiliated hospitals during the early phase of the pandemic. Healthcare Workers Most at Risk for COVID-19.

Research 52

Research Nurses Disease Immune Response 52

The Pharma Data

DECEMBER 3, 2020

An initial analysis of data from 17/22 patients who completed one of these assessments showed substantially decreased neurocognitive abilities compared to children of the same age level despite the use of multiple anti-epileptic therapies. In addition, a gap in adaptive functioning was noted using the Vineland Adaptive Behavior Scales. “We

Clinical Trials 52

Clinical Trials Protein Expression Pharmacokinetics Trials 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. This indication is approved under accelerated approval based on overall response rate and duration of response.

Treatment 52

Treatment Trials Therapies Clinical Trials 52

The Pharma Data

JANUARY 26, 2021

Data published last week showed that bamlanivimab significantly reduced COVID-19 risk for nursing home residents in a Phase III trial. . Eli Lilly’s bamlanivimab, a neutralizing antibody initially developed by AbCellera, was approved for emergency use authorization in November by the U.S.

Virus 52

Virus Trials Nurses Research Laboratories 52

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. who require oxygen therapy due to COVID-19, OR.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

MAY 27, 2022

Consultant Physician in Haematology, University Hospital of Salamanca.* “The of patients with RRMM responding to therapy (98 percent overall response rate ORR ).1,6 In December 2017, Janssen Biotech, Inc. Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc.

Therapies 52

Therapies Treatment Pharmaceutical Companies Nurses 52

The Pharma Data

DECEMBER 3, 2020

Today, transplant patients who do not respond or experience adverse events related to existing therapies may be at higher risk for complications from the virus, including transplant failure and death. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. About Maribavir. Springer Open, 2018.

Treatment 52

Treatment Pharmaceutical Companies Therapies Virus 52

The Pharma Data

APRIL 28, 2021

The positive CHMP opinion is a scientific recommendation for marketing authorization to the European Commission (EC), which is expected to deliver its final decision on VENCLYXTO combination therapy for use in AML in the first half of 2021. Advise nursing women to discontinue breastfeeding during treatment.

Clinical Trials 40

Clinical Trials Trials Treatment Therapies 40

The Pharma Data

DECEMBER 1, 2020

13 to 17 and attracted participants from around the world, including cardiovascular specialists, surgeons, and nurses as well as other health care professionals. AHA: Obese Patients More Likely to Be Hospitalized for COVID-19. AHA: Out-of-Hospital Cardiac Arrest Outcomes Worse During COVID-19. ” Press Release. 13 to 17.

Hospitals 52

Hospitals Disease Treatment Therapies 52

The Pharma Data

MAY 13, 2021

And I was rushed to hospital in the back of an ambulance… As paramedics desperately tried to keep me alive. I could hear doctors and nurses speaking in hushed tones…. And Mary-Anne, a nurse from Arkansas, who says…. I’d always assumed that Jen just did estrogen replacement therapy or something like that…. Jenn told me.

Production 52

Production Packaging Doctors Research 52

The Pharma Data

JUNE 18, 2021

lead investigator of the CLL14 study, hematologist-oncologist at the University Hospital Cologne in Germany , and study physician at the German CLL Study Group. The therapies were administered for a fixed duration of 12 months for VENCLYXTO/VENCLEXTA in combination with six cycles of obinutuzumab. with Ven-Obi versus 83.1%

Treatment 40

Treatment Trials Therapies Clinical Trials 40

The Pharma Data

JANUARY 24, 2021

Innovation Pharmaceuticals received the greenlight from the FDA to initiate a Phase II trial of Brilacidin in hospitalized COVID-19 patients. It was run at nine hospitals in Brazil from May 8 to July 17, 2020. The trial will evaluate a single dose of firibastat 1000mg compared to placebo, on top of the patients’ current therapy.

Long-Term Care Facilities 52

Long-Term Care Facilities Trials Virus Clinical Trials 52